Clinical Trial Update: Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of setmelanotide (RM-493) in obese participants with Prader-Willi syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• Setmelanotide (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Prader-Willi Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2023-07-27